argenx SE (NASDAQ: ARGX) is a leading global immunology company that develops innovative treatments for severe autoimmune diseases. The company's work focuses on advanced antibody-based therapies. Its main product, VYVGART, is used to treat conditions where the body's immune system attacks its own tissues, highlighting its crucial role in biotech innovation.
On May 28, 2026, analyst Alex Thompson from Stifel Nicolaus set a robust price target of $1,255 for argenx SE. At the time, the stock's price was $838.49, which represents a significant potential upside of approximately 49.67%. This strong analyst endorsement suggests a firm belief in the company's future growth potential and stock valuation.
This positive outlook is strongly supported by argenx SE's impressive financial performance. In the first quarter of 2026, the company reported a remarkable 63% year-over-year increase in sales. It also maintained healthy 30% operating margins, indicating strong profitability as it keeps 30 cents of profit for every dollar of sales after covering basic operational costs.
The company is actively expanding its market reach. As highlighted by Seeking Alpha, a recent FDA approval for VYVGART now covers all adult generalized myasthenia gravis (gMG) patients. This crucial regulatory approval significantly increases the number of patients who can benefit from the treatment, further strengthening argenx SE's market position and patient access.
argenx SE is also keenly focused on future developments and biopharmaceutical innovation. The company will host a webinar on June 23, 2026, to discuss its promising clinical program for myositis. Management will also present at two investor conferences in June, sharing valuable insights into its strategic direction and robust pipeline.
